kCBF: Ketone Dose and Cerebral Blood Flow Study

Sponsor
McMaster University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06032156
Collaborator
(none)
20
1
3
10
2

Study Details

Study Description

Brief Summary

Ketone bodies are produced by the liver during periods of food scarcity or severe carbohydrate restriction. Blood ketones are an alternative fuel source used by the brain, heart, and skeletal muscle during periods of fasting. Further, ketones bodies act as a signalling molecule that have pleiotropic effects that upregulate cellular stress-resistance pathways throughout the body.

Oral supplements containing exogenous ketones have recently become available and represent a novel tool for increasing plasma ketone bodies without the need for dietary restriction. Early evidence suggests that oral ketone supplements may enhance cerebral blood flow and improve cognition. However, the dose-dependent effects of a single ketone supplement on cerebral blood flow and cognition in young adults is currently unknown.

The purpose of this study is to characterize the effects of ingesting a high versus low dose of an oral ketone monoester on cerebral blood flow, circulating blood markers, and cognition in young adults.

As an exploratory aim, this study will investigate how oxygen uptake kinetics during submaximal exercise are impacted 2 hours after ingestion of a ketone supplement. Recent findings indicate that ketone supplementation may impair exercise performance due to the physiological stress (i.e., pH disturbances) imposed by an acute ketone dose. Delaying exercise onset by 2 hours after ingestion of a ketone supplement may enhance oxygen kinetics in a dose-dependent manner.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Low Dose β-OHB
  • Dietary Supplement: High Dose β-OHB
  • Other: Placebo
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
A randomized double-blind placebo-controlled crossover design will be used to test 3 conditions. Participants will consume 60 mL of a supplement containing: 1) a low β-OHB dose (0.3g/kg) body weight of the ketone monoester; [R]-3-hydroxybutyl [R]-3-hydroxybutyrate); 2) a high β-OHB dose (0.6g/kg body weight); or 3) a taste-matched calorie-free inert placebo drink.A randomized double-blind placebo-controlled crossover design will be used to test 3 conditions. Participants will consume 60 mL of a supplement containing: 1) a low β-OHB dose (0.3g/kg) body weight of the ketone monoester; [R]-3-hydroxybutyl [R]-3-hydroxybutyrate); 2) a high β-OHB dose (0.6g/kg body weight); or 3) a taste-matched calorie-free inert placebo drink.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
The Acute Effects of a High Versus Low Dose of a Ketone Monoester Supplement on Cerebral Blood Flow and Cognition
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

Single dose of a taste-matched calorie-free placebo

Other: Placebo
Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.

Experimental: High Dose β-OHB

Single dose of a ketone monoester ([R]-3-hydroxybutyl [R]-3-hydroxybutyrate; 0.6 g β-OHB/kg body weight)

Dietary Supplement: High Dose β-OHB
Ingestion of a high dose [R]-3-hydroxybutyl [R]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.

Experimental: Low Dose β-OHB

Single dose of a ketone monoester ([R]-3-hydroxybutyl [R]-3-hydroxybutyrate; 0.3 g β-OHB/kg body weight)

Dietary Supplement: Low Dose β-OHB
Ingestion of a low dose [R]-3-hydroxybutyl [R]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.

Outcome Measures

Primary Outcome Measures

  1. Resting cerebral blood flow (CBF) [2-hour]

    Measured via duplex ultrasound of the extra-cranial arteries (internal carotid and vertebral arteries).

Secondary Outcome Measures

  1. Cognitive Function [2-hour]

    The MST (Mnemonic Similarity Task) will be used to assess hippocampal-dependent memory and pattern separation.

  2. Plasma beta-hydroxybutyrate area under the curve [2-hour]

    Venous blood samples will be obtained via intravenous catheter

  3. Brain-derived neurotrophic factor (BDNF) [2-hour, then following completion of submaximal exercise bout]

    Serum and plasma BDNF measured in venous blood samples will be obtained via intravenous catheter

  4. Oxygen uptake (VO2) [2-hour, then during submaximal exercise (performed after 2-hour rest period)]

    Breath-by-breath analysis performed via metabolic cart

  5. End-tidal CO2 [2-hour, then during submaximal exercise (performed after 2-hour rest period)]

    Breath-by-breath analysis performed via PowerLab Gas Analyzer (AD Instruments)

  6. Mean arterial pressure (MAP) [2-hour]

    Automated blood pressure cuff measurement of brachial artery pressure in mmHg.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Between the ages of 18 and 35
Exclusion Criteria:
  • Presence of obesity (body mass index > 30 kg/m^2)

  • Presence of known cardiovascular disease

  • Presence of type 2 diabetes

  • History of cardiovascular events requiring hospitalization (i.e., heart attack)

  • History of concussion(s) with persistent symptoms

  • Currently following a ketogenic diet and/or taking ketone body supplements

Contacts and Locations

Locations

Site City State Country Postal Code
1 McMaster University Hamilton Ontario Canada L8S 4K1

Sponsors and Collaborators

  • McMaster University

Investigators

  • Principal Investigator: Jeremy J Walsh, PhD, McMaster University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
McMaster University
ClinicalTrials.gov Identifier:
NCT06032156
Other Study ID Numbers:
  • kCBF
First Posted:
Sep 11, 2023
Last Update Posted:
Sep 11, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by McMaster University

Study Results

No Results Posted as of Sep 11, 2023